Clinical Laserthermia Systems appoints new CFO
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announces that Rolf Ho Bornschein has been appointed as the new CFO for CLS. The current CFO, Lars-Erik Eriksson, will leave his present position. However, Lars-Erik, who is one of the co-founders of CLS, retains a central role in the company as a member of the Board.
Rolf Ho Bornschein has extensive international experience from senior positions in both the finance and MedTech sectors, including as a CFO. His most recent role was as Director Tracheostomy and 3PP ENT Sales at Atos Medical AB, which is owned by the Danish MedTech company Coloplast. In the role of CFO, Rolf will also be part of the CLS Executive Management Team. He commences his role on 1 October.
”As CFO and with responsibility for the Group’s finance function, Rolf will support CLS’s continued market establishment and commercialization of our TRANBERG products in the USA, Europe, and the Asia-Pacific region. Rolf has excellent knowledge of finance and accounting. In addition, he will contribute with his extensive experience in business development in the global MedTech sector. We welcome him to CLS,” says Dan J. Mogren, CEO, CLS.
This information is such information that Clinical Laserthermia Systems AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out below on 12 August 2022.
Contact Information:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 – (0)705 – 90 11 40 E-mail: dan.mogren@clinicallaser.com
About CLS and TRANBERG system
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®,
the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se